An extract from Cannabis sativa was approved in Germany in May 2011 for patients suffering from moderate to severe muscle spasms due to multiple sclerosis. Since the manufacturer chose a different appropriate comparator therapy, no proof of added benefit of Cannabis sativa can be derived from the manufacturer’s dossier. This is the conclusion of a new assessment.